A DNA damage repair deficient group in prostate cancer
Research type
Research Study
Full title
The identification of a DNA damage repair deficient group in prostate cancer.
IRAS ID
124801
Contact name
Stephen Liggett
Contact email
Sponsor organisation
Queens University Belfast
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
The current treatment options for advanced and metastatic prostate cancer are largely palliative. These treatments have relapse rates of over 80% in the advanced and virtually 100% in the metastatic setting. This demonstrates that there is a clear clinical need for new treatment options. In breast cancer we have identified a subgroup of tumours that have defective DNA repair processes (DDRD). This group demonstrates an improved response rate to DNA damaging based chemotherapies such as cyclophosphamide (odds ratio 4.01). The aim of this project is to profile a series of prostate cancer samples from patients treated with a range of chemotherapies to establish if a) the group identified in breast cancer is also present in prostate cancer b) if patients identified as being DDRD demonstrated better responses to DNA damaging chemotherapies, c) if patients identified as being DDRD demonstrated worse responses to taxane based chemotherapies and d) develop a prostate specific signature with cut-off values that will prospectively assign if a prostate cancer is DDRD positive or negative.
REC name
North West - Preston Research Ethics Committee
REC reference
14/NW/1480
Date of REC Opinion
1 Dec 2014
REC opinion
Favourable Opinion